Market Newsdesk

Everbridge Teams with The Associated Press (AP) to Integrate Global News Report into Market-Leading Critical Event Management (CEM) Platform

• Everbridge expands its market-leading risk intelligence offering to over 25,000 data sources, helping businesses, governments, and healthcare organizations correlate the things they care about (employees, citizens, facilities, supply chain, IT infrastructure) with real-time risks, in order to mitigate impact and accelerate response
• By adding AP breaking and geopolitical news into its Critical Event Management platform, Everbridge provides its customers with enhanced contextualization of risk data leveraging the reporting, speed and deep expertise of AP journalists in 250 locations worldwide

BURLINGTON, Mass.–(BUSINESS WIRE)–Everbridge, Inc. (NASDAQ:EVBG), the global leader in critical event management (CEM), and The Associated Press (AP) today announced a collaboration that will incorporate AP’s global news reports into the Everbridge Critical Event Management (CEM) platform. The collaboration will provide Everbridge customers with AP’s deep subject-matter expertise and extensive contextualization of risk data from critical events happening across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005689/en/

Through machine learning and AI-enabled incident collection, Everbridge combines more than 25,000 of the most trustworthy data sources with an experienced team of analysts, creating the industry’s leading source of verified data and hyper local threat intelligence.

An independent global news organization with journalists in 250 locations in 100 countries, AP journalism is seen by more than half the world’s population each day through text stories, photos, videos, and live video coverage. For more than 175 years, AP journalists have kept the world informed of the biggest stories – from the COVID-19 pandemic to presidential elections to natural disasters.

Sourcing information from AP will allow Everbridge to provide enterprises and governments with one of the world’s top news feeds, curated along with thousands of additional risk sources. Leveraging comprehensive risk intelligence and contextualized situational analysis remains critical to how organizations effectively achieve enterprise resilience across digital and physical domains.

“We are excited to work with Everbridge to further expand the impact of AP’s geopolitical news coverage and broaden the number of organizations benefiting from the expertise of AP’s on-the-ground journalists around the world,” said Tom Januszewski, AP vice president of global business development. “AP’s journalism is trusted, reliable, accurate and fast, and we are pleased it will be used to help Everbridge clients react faster to critical events.”

Everbridge curates threat intelligence from risk data feeds monitoring weather, wildfires, floods, supply chain disruptions, man-made violence, terror threats and cyberattacks, among hundreds of other categories. Everbridge’s comprehensive, configurable risk monitoring capabilities deliver actionable information that helps reduce risk wherever people live, work, or travel. This intelligence helps to correlate, for example, the proximity of corporate assets to potential locations that may be subject to elevated risk. Risk visibility allows corporate security teams to easily determine required additional action to protect employees and assets around the world.

“Regarded as a top source for news from all corners of the world, AP provides extensive contextual content on real-time world events,” said Karl Kotalik, VP of global risk intelligence solutions. “By combining in-depth news reporting and analysis with risk event correlation, Everbridge provides our customers with the most comprehensive context to make informed decisions to manage and respond to risk.”

Everbridge’s end-to-end CEM platform digitally transforms how organizations manage and respond to critical events, helping organizations safeguard and enable revenue while reducing expenses. CEM can be deployed rapidly on a modular basis supporting hundreds of positive-ROI use cases including for people and life safety, operations and business continuity, supply chain risk, IoT and the smart enterprise, and IT incidents.

Everbridge customers include some of the largest firms and leaders in their respective industries including Fortune 1000 businesses such as Bristol Myers Squibb, Cisco, CVS Health, Goldman Sachs, Lowe’s, Tiffany & Co., chemical giant Dow, telecom consumer electronics company Nokia, as well as some of Silicon Valley’s leading tech giants, global e-commerce firms, oil and natural gas providers, hotel and hospitality chains, automotive, aerospace and defense technology, air travel, and major car rental firms.

Customers can also utilize Everbridge to share intelligence with other organizations and to coordinate response through the CEM platform, either publicly or privately. Everbridge’s support teams have established a multitude of private networks among law enforcement, hospitals, airports, universities and enterprises around the world so they can share critical event-related updates.

About AP

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day. Online: www.ap.org

About Everbridge

Everbridge, Inc. (NASDAQ:EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Organizations Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,700 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication modalities, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 25 cities around the globe. For more information visit www.everbridge.com.

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 26, 2021. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005689/en/

Everbridge:

Jeff Young

Media Relations

[email protected]

781-859-4116

Joshua Young

Investor Relations

[email protected]

781-236-3695

AP:

Lauren Easton

Global Director of Media Relations and Corporate Communications

[email protected]

212-621-7005

Patrick Maks

Media Relations Manager

[email protected]

212-621-7536

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Data Management Communications Security Technology Software Networks Publishing

MEDIA:

Photo

Everbridge Teams with The Associated Press (AP) to Integrate Global News Reports into Market-Leading Critical Event Management (CEM) Platform (Graphic: Business Wire)

Logo

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

ARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity

ARCT-154, Arcturus’ STARR™ mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers against all variants tested in primates, including the Delta variant

ARCT-154 to begin staged Phase 3 study in Vietnam; potential for EUA in December

Investor conference call at 4:30 p.m. ET today

SAN DIEGO–(BUSINESS WIRE)–
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2021 and provided corporate updates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005702/en/

“This has been an exceptionally productive period where Arcturus has made substantial progress with our mRNA-based vaccine and therapeutic platforms. We are excited about the imminent initiation of the global Phase 3 vaccine trial of ARCT-021, which is funded by a global entity. We made excellent progress advancing and partnering ARCT-154, our next generation vaccine, which targets SARS-CoV-2 variants, including the rapidly expanding and highly transmissible Delta variant. In addition to the progress with our vaccine franchise, we’ve also advanced our therapeutics pipeline, with the approval of a multiple dose Phase 2 study with ARCT-810, our systemically administered mRNA therapeutic candidate for individuals with OTC deficiency,” said Joseph Payne, President and CEO of Arcturus.

Recent Corporate Highlights

• ARCT-021 has been selected by a global entity for inclusion in a multinational Phase 3 vaccine trial against COVID-19. The placebo-controlled study plans to enroll tens of thousands of participants and will evaluate a 5-mcg dose of ARCT-021 administered as a single injection regimen. The Phase 3 study will be sponsored and funded by the entity.

• Arcturus announced an agreement with Vinbiocare, whereby Vinbiocare will fully fund and establish a facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines. In addition to the $40 million upfront payment, Vinbiocare will purchase the mRNA drug substance from Arcturus and pay a royalty on manufactured doses.

• Arcturus has advanced ARCT-154, our next generation STARR™ mRNA vaccine candidate targeting SARS-CoV-2 variants of concern, toward multiple clinical development studies. Preclinical data demonstrate strong neutralizing immunogenicity in non-human primates to SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants. ARCT-154 elicits 14.4 to 25.9-fold higher neutralizing antibody titers than ARCT-021 in non-human primates, including an observed increase of 17.8-fold higher neutralizing antibody titers against the Delta variant.

ARCT-154 utilizes an optimized STARR™ mRNA with multiple improvements, including modifications for stability and translation, increased immunogenicity of the spike protein antigen via amino acid substitution, expressing the spike protein in a pre-fusion state, and inactivating the furin cleavage site.

Neutralizing Titers (Geo Mean NT50) Against Variants of Concern in Cynomolgus Macaques One Month Post Dose 2
STARR™ Vaccine	Ancestral	Alpha	Beta	Gamma	Delta
ARCT-021 (7.5 mcg x 2)	1,438	603	54	50	386
ARCT-154 (7.5 mcg x 2)	20,773	9,080	874	1,297	6,876
Fold Improvement	14.4	15.1	16.2	25.9	17.8
Non-Human Primate (NHP) data collected one month after second dose of 7.5 mcg; analysis of NHP serum was performed using non-replicating vesicular stomatitis virus pseudo-typed with the spike protein of the SARS-CoV-2 variants of concern indicated. Titers (geometric mean) were determined by calculating the dilution that resulted in 50% inhibition of cells expressing GFP encoded by the pseudovirus, a surrogate of virus infection. Error bars indicate geometric standard deviation.

T cell responses for ARCT-021 and ARCT-154 are robust and similar in non-human primates. Notably, STARR™ mRNA vaccines elicit similar T cell responses against all variants of concern tested. The robust T cell responses are attributed to the self-amplifying mRNA mechanism of antigen expression.

• Arcturus announced approval of a Clinical Trial Application (CTA) from the Singapore Health Sciences Authority (HSA) enabling the advancement of ARCT-154 into a Phase 1/2 clinical trial to evaluate the vaccine as a primary vaccination series and as a booster following initial vaccination with Comirnaty® (marketed by Pfizer and BioNTech). The Phase 1/2 trial costs are funded in part from a previously secured grant from Singapore.

• Arcturus announced that the company’s partner Vinbiocare received approval for a CTA from the Vietnam Ministry of Health to advance ARCT-154 into a Phase 1/2/3 clinical study. The trial is a randomized, observer-blind, placebo-controlled design, and is sponsored and completely funded by Vinbiocare. The Phase 1/2/3 study will assess the safety, immunogenicity and efficacy in up to 21,000 adults, with potential Emergency Use Authorization (EUA) by the Vietnam Ministry of Health in December 2021.

• Arcturus announced approval from the UK Health Research Authority to initiate a multiple dose Phase 2 clinical study for ARCT-810, a novel mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) Deficiency. The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency. ARCT-810 Phase 2 study interim results in a subset of participants are expected in H2 2022.

Financial Results for the Quarter Ended June 30, 2021

Revenues in conjunction with strategic alliances and collaborations: Arcturus’ primary sources of revenues were from license fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended June 30, 2021, the Company reported revenue of $2.0 million compared with $2.3 million for the three months ended June 30, 2020.

Operating expenses: Total operating expenses for the three months ended June 30, 2021, were $55.7 million compared with $12.4 million for the three months ended June 30, 2020 and $59.8 million for the three months ended March 31, 2021.

Research and development expenses increased by approximately $37.7 million year over year in the second quarter ended June 30, 2021 due to increased personnel costs as well as expenses related to our ARCT-810 and ARCT-021 programs. Research and development declined by approximately $5 million sequentially in the June 2021 quarter due primarily to the one-time $5 million exclusive license cost from Alexion Pharmaceuticals in the first quarter of 2021.

For the three months ended June 30, 2021, Arcturus reported a net loss of approximately $54.6 million, or ($2.07) per basic and diluted share, compared with a net loss of $10.3 million, or ($0.55) per basic and diluted share in the three months ended June 30, 2020.

The Company’s cash balance totaled $433.6 million as of June 30, 2021, compared to a cash balance of $462.9 million at December 31, 2020. Subsequent to the end of the quarter, the company received the remaining $30 million of our upfront payment from Vinbiocare. Based on our current pipeline, the Company’s cash position is expected to be sufficient to support operations for more than two years.

Monday, August 9th @ 4:30 p.m. ET
Domestic:	877-407-0784
International:	201-689-8560
Conference ID:	13721797
Webcast:	http://public.viavid.com/index.php?id=145873

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (229 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, collaborations, the planned initiation, design or completion of clinical trials, anticipated sponsorship and/or funding of clinical trials of our candidates, the likelihood that the Company will obtain clearance from regulatory authorities to proceed with planned clinical trials, the ability to enroll subjects in clinical trials, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe, the anticipated timing for regulatory submissions, the timing of, and expectations for, any results of any preclinical or clinical studies or regulatory approvals, the likelihood of success (including safety and efficacy) of the Company’s pipeline, including ARCT-021, ARCT-154 and ARCT-810, the potential administration regimen or dosage, or ability to administer multiple doses of, any of the Company’s drug candidates, the Company’s efforts to develop a vaccine against COVID-19 and therapeutic potential thereof based on the Company’s mRNA therapeutics, the Company’s manufacturing methods and technologies, the likelihood that a patent will issue from any patent application, its current cash position and adequacy of its capital to support future operations, and the impact of general business and economic conditions. Actual results and performance could differ materially from those projected in any forward-looking statements as a result of many factors including, without limitation, the ability to enroll subjects in clinical trials as a result of the COVID-19 pandemic, the impact of commercialization of third-party COVID-19 vaccines on the design, and ability to conduct, clinical trials, the availability of manufacturing capacity and raw materials, unexpected clinical results, government regulations impacting the regulatory environment or intellectual property landscape, and general market conditions that may prevent such achievements or performance. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Trademark Acknowledgements

The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR® and STARR™, are the property of Arcturus. All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value information)
		June 30, 2021				March 31, 2020				December 31, 2020
		(unaudited)				(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	433,574			$	466,839			$	462,895
Accounts receivable			2,163				2,007				2,125
Prepaid expenses and other current assets			2,301				1,150				2,769
Total current assets			438,038				469,996				467,789
Property and equipment, net			3,407				3,427				3,378
Operating lease right-of-use asset, net			6,341				6,690				5,182
Equity-method investment			920				1,248				—
Non-current restricted cash			107				107				107
Total assets		$	448,813			$	481,468			$	476,456
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	10,084			$	5,597			$	10,774
Accrued liabilities			42,614				29,800				20,639
Deferred revenue			18,071				17,936				18,108
Total current liabilities			70,769				53,333				49,521
Deferred revenue, net of current portion			9,850				11,313				12,512
Long-term debt, net of current portion			56,309				58,147				13,845
Operating lease liability, net of current portion			5,359				5,710				4,025
Other long-term liabilities			878				358				—
Total liabilities		$	143,165			$	128,861			$	79,903
Stockholders’ equity
Common stock: $0.001 par value; 60,000 shares authorized; 26,327 issued and outstanding at June 30, 2021, 26,319 issued and outstanding at March 31, 2021 and 26,192 issued and outstanding at December 31, 2020			26				26				26
Additional paid-in capital			560,365				552,743				540,343
Accumulated deficit			(254,743	)			(200,162	)			(143,816	)
Total stockholders’ equity			305,648				352,607				396,553
Total liabilities and stockholders’ equity		$	448,813			$	481,468			$	476,456

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands except per share data)
		Three Months Ended
		June 30,								March 31,
		2021				2020				2021
Collaboration revenue		$	2,001			$	2,322			$	2,127
Operating expenses:
Research and development, net			45,679				7,944				50,050
General and administrative			10,042				4,420				9,743
Total operating expenses			55,721				12,364				59,793
Loss from operations			(53,720	)			(10,042	)			(57,666	)
(Loss) gain from equity-method investment			(328	)			(100	)			1,248
(Loss) gain from foreign currency			(13	)			—				430
Finance expense, net			(520	)			(121	)			(358	)
Net loss		$	(54,581	)		$	(10,263	)		$	(56,346	)
Net loss per share, basic and diluted		$	(2.07	)		$	(0.55	)		$	(2.15	)
Weighted-average shares outstanding, basic and diluted			26,323				18,794				26,243
Comprehensive loss:
Net loss		$	(54,581	)		$	(10,263	)		$	(56,346	)
Comprehensive loss		$	(54,581	)		$	(10,263	)		$	(56,346	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005702/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

(858) 900-2682

[email protected]

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

[email protected]

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical General Health Health Infectious Diseases Clinical Trials

MEDIA:

Logo

Photo

Non-Human Primate (NHP) data collected one month after second dose of 7.5 mcg; analysis of NHP serum was performed using non-replicating vesicular stomatitis virus pseudo-typed with the spike protein of the SARS-CoV-2 variants of concern indicated. Titers (geometric mean) were determined by calculating the dilution that resulted in 50% inhibition of cells expressing GFP encoded by the pseudovirus, a surrogate of virus infection. Error bars indicate geometric standard deviation. (Photo: Business Wire)

Photo

T cell responses from non-human primates assessed one month after second dose of 7.5 mcg; SARS-CoV-2 spike specific T cell responses were analyzed by ELISpot assay using overlapping 15-mer peptides spanning the entire spike antigen from the ancestral SARS-CoV-2 strains or the Alpha, Beta, and Gamma variants of concern. Spot Forming Units (SFU) were determined after background subtraction of unstimulated controls. Bars indicate mean values and error bars indicate standard deviation. (Photo: Business Wire)

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial launch of its lead product, tab-cel^®.

“From commercialization of innovative rare oncology therapies to payer, access and reimbursement expertise, Ameet brings a wealth of experience in the cell and gene therapy space to the Atara Board,” said Pascal Touchon, President and Chief Executive Officer of Atara. “Ameet joins us at a critical time as we advance our first-in-kind off-the-shelf allogeneic T-cell immunotherapy and anticipate our first approvals in 2022. I am thrilled to welcome him to our Board.”

Ameet Mallik is Chief Executive Officer of Rafael Holdings, a late-stage cancer metabolism therapeutic company and has held several leadership roles at Novartis Oncology, most recently as Executive Vice President and Head of U.S. Oncology where he was responsible for commercial and medical oncology operations. Before leading U.S. Oncology, Mr. Mallik served as the Global Head, Marketing, Value and Access as well as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik held several commercial leadership roles earlier in his career at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables and has previously worked as an Associate Principal at McKinsey and Company.

“Atara Biotherapeutics is an industry trailblazer for allogeneic T-cell immunotherapy and is rapidly advancing a robust pipeline,” said Mr. Mallik. “I am honored to join the Board and look forward to working with my fellow directors and the entire Atara leadership team to advance the company’s mission to transform the lives of patients with serious diseases.”

Mr. Mallik received a B.S. in Chemical Engineering and an M.S. in Biotechnology from Northwestern University and an M.B.A. from The Wharton School at the University of Pennsylvania.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel^® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV⁺ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: Mr. Mallik joining Atara’s Board of Directors and the related effective date; Atara’s portfolio, pipeline, technology and platform; the timing of potential tab-cel^® approval, and Atara’s ability to successfully advance the development of its portfolio, pipeline, technology and platform and commercialization of tab-cel^®. Because such statements deal with future events and are based on Atara Biotherapeutics’ current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Biotherapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the ongoing COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara’s cash resources and need for additional capital; and other risks and uncertainties affecting Atara’s and its development programs, including those discussed in Atara Biotherapeutics’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara Biotherapeutics disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005701/en/

Investors

Eric Hyllengren

805-395-9669

[email protected]

Media

Alex Chapman

805-456-4772

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Research Genetics Clinical Trials Stem Cells Biotechnology General Health Pharmaceutical Health Science Oncology

MEDIA:

Logo

SkyWest Announces Flying Agreement with Delta for 16 New E175s

• SkyWest to purchase and operate the aircraft under a multi-year contract with Delta, with the first aircraft scheduled for delivery in the second quarter of 2022.
• The aircraft will be owned and financed by SkyWest.
• The 16 new E175s are expected to replace 16 SkyWest CRJ900s currently operating under the Delta contract.

ST. GEORGE, Utah–(BUSINESS WIRE)–
SkyWest, Inc. (NASDAQ: SKYW) (“SkyWest”) today announced an agreement with Delta Air Lines (“Delta”) to purchase and operate 16 new E175 aircraft under a multi-year capacity purchase agreement. These aircraft are scheduled to be placed into service beginning in the first half of 2022, and will be placed into service ratably through year-end 2022. The aircraft will be purchased by SkyWest from Embraer and delivered new from the factory. SkyWest continues to be the largest owner/operator of the Embraer E175 aircraft in the world.

“We are pleased to continue to strengthen our Delta agreement with these new, dual-class aircraft,” said Chip Childs, President and CEO of SkyWest. “The E175 continues to serve our partners and passengers well as we help our partners work toward full domestic recovery.”

SkyWest expects the 16 new E175 aircraft will replace 16 SkyWest-owned or financed CRJ900s currently under its Delta contract, with expirations ranging from the second half of 2022 to early 2023. SkyWest is evaluating the impact of the anticipated displacement of the CRJ900s, including a potential non-cash impairment charge.

About SkyWest

SkyWest, Inc. is the holding company for SkyWest Airlines and SkyWest Leasing, an aircraft leasing company. SkyWest Airlines has a fleet of over 450 aircraft connecting passengers to over 230 destinations throughout North America. SkyWest Airlines operates through partnerships with United Airlines, Delta Air Lines, American Airlines and Alaska Airlines carrying more than 21 million passengers in 2020 and 43 million passengers in 2019.

Forward Looking-Statements

In addition to historical information, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “forecasts,” “expects,” “intends,” “believes,” “anticipates,” “estimates,” “should,” “likely” and similar expressions identify forward-looking statements. Such statements include, but are not limited to, statements about the expected timing of delivery of new aircraft under, and other benefits of, the new flying agreement with Delta, statements about the expected timing of the expiration or displacement of currently owned or financed aircraft, as well as SkyWest’s future financial and operating results, plans, objectives, expectations, estimates, intentions and outlook, and other statements that are not historical facts. All forward-looking statements included in this release are made as of the date hereof and are based on information available to SkyWest as of such date. SkyWest assumes no obligation to update any forward-looking statements unless required by law. Readers should note that many factors could affect the future operating and financial results of SkyWest and could cause actual results to vary materially from those expressed in forward-looking statements set forth in this release. These factors include, but are not limited to, uncertainties regarding the uncertainty of the duration, scope and impact of COVID-19, a further spread or worsening of COVID-19, the consequences of the COVID-19 outbreak to economic conditions, the travel industry and our major partners in general and the financial condition and operating results of SkyWest in particular, the prospects of entering into agreements with existing or other carriers to fly new aircraft, ongoing negotiations between SkyWest and its major partners regarding their contractual obligations, uncertainties regarding operation of new aircraft, the ability to attract and retain qualified pilots, the impact of regulatory issues such as pilot rest rules and qualification requirements, and the ability to obtain aircraft financing.

Actual operational and financial results of SkyWest will likely also vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of other reasons, including, in addition to those identified above: the existing global COVID-19 pandemic and the outbreak of any other disease or similar public health threat that affects travel demand or travel behavior; the challenges of competing successfully in a highly competitive and rapidly changing industry; developments associated with fluctuations in the economy and the demand for air travel, including related to the duration and impact of the COVID-19 pandemic, and related decreases in customer demand and spending; the financial stability of SkyWest’s major partners and any potential impact of their financial condition on the operations of SkyWest; fluctuations in flight schedules, which are determined by the major partners for whom SkyWest conducts flight operations; variations in market and economic conditions; significant aircraft lease and debt commitments; estimated useful life of long-lived assets, residual aircraft values and related impairment charges; labor relations and costs; the impact of global instability; rapidly fluctuating fuel costs, and potential fuel shortages; the impact of weather-related or other natural disasters on air travel and airline costs; aircraft deliveries; and other unanticipated factors. Risk factors, cautionary statements and other conditions which could cause SkyWest’s actual results to differ materially from management’s current expectations are contained in SkyWest’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Additionally, the risks, uncertainties and other factors set forth above or otherwise referred to in the reports that the Company files with the Securities and Exchange Commission may be further amplified by the global impact of the COVID-19 pandemic.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005676/en/

Investor Relations

435.634.3200

[email protected]

Corporate Communications

435.634.3553

[email protected]

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Transport Air

MEDIA:

Logo

Watts Water Technologies to Participate in Seaport Research Partners Annual Virtual Summer Investor Conference

NORTH ANDOVER, Mass.–(BUSINESS WIRE)–
Watts Water Technologies, Inc. (NYSE: WTS) today announced that Robert J. Pagano, Jr., CEO; Shashank Patel, CFO and Timothy M. MacPhee, Treasurer & Vice President of Investor Relations, will participate in the Seaport Research Partners Annual Virtual Summer Investor Conference on Tuesday, August 24, 2021 starting at 8:00 a.m. Eastern Time.

Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world. Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions for commercial, residential, and industrial applications. For more information, visit www.wattswater.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005669/en/

Watts Water Technologies, Inc.

Timothy MacPhee

Treasurer & Vice President

Investor Relations

Phone: 978-689-6201

Fax: 978-794-0353

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Construction & Property Building Systems

MEDIA:

Logo

Watts Water Technologies to Participate in Seaport Research Partners Annual Virtual Summer Investor Conference

NORTH ANDOVER, Mass.–(BUSINESS WIRE)–
Watts Water Technologies, Inc. (NYSE: WTS) today announced that Robert J. Pagano, Jr., CEO; Shashank Patel, CFO and Timothy M. MacPhee, Treasurer & Vice President of Investor Relations, will participate in the Seaport Research Partners Annual Virtual Summer Investor Conference on Tuesday, August 24, 2021 starting at 8:00 a.m. Eastern Time.

Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world. Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions for commercial, residential, and industrial applications. For more information, visit www.wattswater.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005666/en/

Watts Water Technologies, Inc.

Timothy MacPhee

Treasurer & Vice President

Investor Relations

Phone: 978-689-6201

Fax: 978-794-0353

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Environment Commercial Building & Real Estate Construction & Property Engineering Utilities Manufacturing Building Systems Energy Residential Building & Real Estate

MEDIA:

Logo

Adamas Reports Second Quarter 2021 Financial Results

Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020

GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020

EMERYVILLE, Calif.–(BUSINESS WIRE)–
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights.

“We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth,” said Neil F. McFarlane, Chief Executive Officer. “We remain on track to achieve our 2021 goals as we navigate the fluid macro environment. With the continued momentum of our GOCOVRI launch alongside our disciplined approach to capital allocation, we are excited about the opportunities ahead for patients and shareholders.”

Recent portfolio highlights

• Total revenues were $22.0 million in the second quarter of 2021, an increase of 17% as compared to $18.8 million in the second quarter of 2020.
• GOCOVRI® (amantadine) extended release capsules product sales were $20.1 million in the second quarter of 2021, an increase of 12% as compared to $18.0 million in the second quarter of 2020.
• New paid prescriptions (NRx) of GOCOVRI were approximately 730 in the second quarter of 2021, a 97% increase over NRx of approximately 370 in the second quarter of 2020.
• Total paid prescriptions (TRx) of GOCOVRI were approximately 9,400 in the second quarter of 2021, a 19% increase over approximately 7,915 TRx in the second quarter of 2020.
• Strong patient persistence of 45%-50% at 12 months for the second quarter of 2021 remains consistent.

Corporate highlights

• Recent publications in peer-reviewed journals: new data analyses suggesting GOCOVRI may meaningfully reduce the impact of motor symptoms on activities of daily living published in Neurology and Therapy; and a review article by leading neurologists published in TouchNEUROLOGY supporting GOCOVRI as a clinically significant advance in treating motor complications.
• Announced issuance of patents for GOCOVRI, the first in a new patent family, which cover drug product composition and method of use.
• First international patent covering ADS-4101, an investigational high-dose, modified release lacosamide capsule for partial onset seizures in patients with epilepsy was issued in Japan. This patent follows two recently issued U.S. patents. These patents may assist efforts to continue to partner or out-license this program.
• Received FDA approval of an sNDA for a second and alternative packager for GOCOVRI further bolstering the Company’s supply chain.

Financial results

Revenue

Total revenues were $22.0 million for the second quarter of 2021, consisting of GOCOVRI product sales of $20.1 million, OSMOLEX ER product sales of $0.5 million and royalty revenue earned on net sales of NAMZARIC® (memantine hydrochloride extended release and donepezil hydrochloride) capsules of $1.4 million. GOCOVRI product sales were up 12% compared to $18.0 million in the same period in 2020.

Research and Development (R&D) expenses

R&D expenses for the second quarter of 2021 were $1.4 million, compared to $2.6 million for the same period in the prior year. The decrease in R&D expenses was primarily due to the completion of the Company’s open-label extension trial for the treatment of multiple sclerosis patients with walking impairment.

Selling, General and Administrative (SG&A) expenses

SG&A expenses for the second quarter of 2021 were $29.2 million, compared to $23.2 million for the same period in the prior year. SG&A expenses in the second quarter of 2021 were primarily attributable to sales force costs and external spend dedicated to GOCOVRI commercialization and the related administrative support as well as the integration and initial promotion of OSMOLEX ER.

Net loss

Net loss was $12.3 million, or $0.27 per share, basic and diluted, for the second quarter of 2021, compared to a net loss of $10.6 million, or $0.37 per share, basic and diluted, for the second quarter of 2020. Net loss for the second quarter of 2021 and 2020 included $1.9 million and $1.7 million, respectively, in non-cash stock-based compensation expense.

Cash and investments

As of June 30, 2021, Adamas had $118.3 million of cash, cash equivalents and available-for-sale securities, compared to $83.4 million as of December 31, 2020. During the first quarter of 2021, the Company raised net proceeds of approximately $66.5 million through the sale of common stock.

Full year 2021 expense guidance

For full year 2021, Adamas is reiterating its estimates for R&D, SG&A and stock-based compensation expenses as set forth below:

		Full Year 2021
R&D expenses		$5 million — $10 million1
SG&A expenses		$110 million — $120 million2
Total operating expenses		$115 million — $130 million3

¹Includes stock-based compensation expense of $1 million.

²Includes stock-based compensation expense of $8 million.

³Includes stock-based compensation expense of $9 million.

Investor conference call and webcast

Adamas will host a conference call and webcast today, August 9, 2021, at 4:30 p.m. ET (1:30 p.m. PT). The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13720109. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.

About GOCOVRI

GOCOVRI® (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes.

Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.

For more information about GOCOVRI, please visit www.GOCOVRI.com.

About OSMOLEX ER

OSMOLEX ER® (amantadine) extended release tablets, is FDA-approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions (EPR) in adult patients. Drug-induced EPR are involuntary, uncontrollable movements often caused by antipsychotic drug use, that can cause significant disruption for patients and their families.

OSMOLEX ER has an immediate release outer layer and an extended release core and is taken in the morning. The most commonly observed adverse reactions with OSMOLEX ER include nausea, dizziness, lightheadedness, and insomnia.

For more information about OSMOLEX ER, please visit www.OSMOLEX.com.

NAMZARIC

For more information, please visit www.NAMZARIC.com.

About Adamas

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Forward-looking statements

Statements contained in this press release regarding matters that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas’ expectations of its full year 2021 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development and commercial activities relating to GOCOVRI, OSMOLEX ER, and ADS-5102, and the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2021, particularly under the caption “Risk Factors.” In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Adamas Pharmaceuticals, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share data)
		Three Months Ended June 30,								Six Months Ended June 30,
		2021				2020				2021				2020
Revenues:
Product sales		$	20,557			$	17,954			$	38,535			$	32,435
Royalty revenue		1,415				840				2,748				840
Total revenues		21,972				18,794				41,283				33,275
Costs and operating expenses:
Cost of product sales		527				381				912				953
Research and development		1,448				2,550				3,260				5,015
Selling, general and administrative, net		29,152				23,177				55,791				47,729
Total costs and operating expenses		31,127				26,108				59,963				53,697
Loss from operations		(9,155)				(7,314)				(18,680)				(20,422)
Interest and other income, net		280				215				664				299
Interest expense		(3,469)				(3,467)				(6,901)				(7,091)
Net loss		$	(12,344)			$	(10,566)			$	(24,917)			$	(27,214)
Net loss per share, basic and diluted		$	(0.27)			$	(0.37)			$	(0.62)			$	(0.97)
Weighted average shares used in computing net loss per share, basic and diluted		45,464				28,194				40,344				28,112

Adamas Pharmaceuticals, Inc. Unaudited Consolidated Balance Sheet Data (in thousands)
		June 30, 2021				December 31, 2020
Cash, cash equivalents, and available-for-sale securities		$	118,256			$	83,365
Total assets		150,644				120,029
Total current liabilities		21,824				34,867
Long-term debt		125,541				126,307
Total liabilities		154,677				170,005
Total stockholders’ deficit		(4,033)				(49,976)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005601/en/

Media:

Sarah Mathieson

Vice President, Corporate Communications

510-450-3528

[email protected]

Investors:

Peter Vozzo

Westwicke/ICR

443-213-0505

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo

ZY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Zymergen Inc. Class Action Lawsuit

SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers of Zymergen Inc. (NASDAQ: ZY) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zymergen’s April 2021 initial public offering (“IPO”) have until October 4, 2021 to seek appointment as lead plaintiff in the Zymergen class action lawsuit. The Zymergen class action lawsuit charges Zymergen, certain of its officers and directors, and the underwriters of Zymergen’s IPO with violations of the Securities Act of 1933. The Zymergen class action lawsuit (Shankar v. Zymergen Inc., No. 21-cv-06028) was commenced on August 4, 2021 and is pending in the Northern District of California.

If you wish to serve as lead plaintiff of the Zymergenclass action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchezof Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Zymergenclass action lawsuit must be filed with the court no later than October 4, 2021.

CASE ALLEGATIONS: The Zymergen class action lawsuit alleges that Zymergen’s Registration Statement was materially false and misleading and omitted to state that: (i) during the qualification process for Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers’ processes; (ii) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (iii) as a result, Zymergen overestimated demand for its products; (iv) consequently, Zymergen’s product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (v) thus, defendants’ positive statements about Zymergen’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 3, 2021, Zymergen issued a business update stating that it “recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections.” Specifically, “several key target customers encountered technical issues in implementing Hyaline into their manufacturing processes,” and Zymergen also found that its total addressable market appears to be smaller than previously expected. As a result, Zymergen “no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.” Zymergen also announced that its CEO was stepping down, effective immediately. On this news, Zymergen’s stock price fell approximately 76%, damaging investors.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Zymergen common stock pursuant and/or traceable to the Registration Statement issued in connection with Zymergen’s IPO to seek appointment as lead plaintiff in the Zymergen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Zymergen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Zymergen class action lawsuit. An investor’s ability to share in any potential future recovery of the Zymergen class action lawsuit is not dependent upon serving as lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs’ firm. Please visit https://www.rgrdlaw.com/firm.html for more information.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005057/en/

Robbins Geller Rudman & Dowd LLP

655 W. Broadway, San Diego, CA 92101

J.C. Sanchez, 800-449-4900

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo